ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: diabetes

Air Pollution May Increase the Risk of RA & RA-Associated ILD

Arthritis & Rheumatology  |  June 25, 2025

Exposure to air pollution, such as high levels of particulate matter from fire smoke and fossil fuel-related nitrogen oxides, may increase the risk of rheumatoid arthritis (RA) and RA-associated interstitial lung disease (ILD), according to Kronzer et al. Their findings highlight the need for improved monitoring of air pollutants and suggest that addressing air pollution may help prevent RA and RA-associated ILD.

Filed under:ConditionsRheumatoid Arthritis Tagged with:air pollutionArthritis & Rheumatologyenvironmental factorILDinterstitial lung disease (ILD)Rheumatoid Arthritis (RA)

3 AC&R Study Summaries: SLE Mortality Risk, Heart Failure & RA, & a Phone-Based Walking Program

Arthritis Care & Research  |  May 12, 2025

Risk of Mortality from SLE By Ansaam Daoud, MD, Loai Dweik, MD, & Omer Pamuk, MD Why was this study done? Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with significant mortality, particularly affecting racial and ethnic minorities. This study aimed to assess national SLE mortality trends over the past two decades, stratified by…

Filed under:ConditionsResearch RheumRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:ExerciseExercise/physical therapyHeart Diseasemortality ratePhysical TherapyRA Resource CenterReading RheumSLE Resource Centerwalking

What Can I Eat or Not Eat to Cure My Arthritis?

Kim Arrey, DtP  |  April 7, 2025

“What can I eliminate from my diet to cure my arthritis?” is the question every client with arthritis asks me. Numerous case reports document patients who achieved lower markers of inflammation and reduced pain and stiffness associated with the removal of one or two food groups from a diet, but historically, no compelling evidence has…

Filed under:Conditions Tagged with:Dietgut microbiomegut microbiotaMediterranean dietnutrition

Potential Biologic Drug Treatment for IgG4-RD Identified

Deborah Levenson  |  March 6, 2025

Inebilizumab reduces the risk of immunoglobulin G4-related disease (IgG4-RD) flares and increases the likelihood of flare-free, complete remission at one year, a recent study shows.1 The randomized, doubleblind, placebo-controlled MITIGATE trial showed that inebilizumab reduced the risk of IgG4-RD symptoms by 87%, compared with placebo. About IgG4-RD IgG4-RD is chronic, rare condition that has, so…

Filed under:Drug UpdatesResearch Rheum Tagged with:B cell depletionIgG4-RDinebilizumab

Metabolic Syndrome & RA Treatment Response

Arthritis & Rheumatology  |  February 26, 2025

Research from Baker et al. demonstrated a strong association between the presence of metabolic syndrome and lower response rates to advanced therapies in patients with RA.

Filed under:ConditionsRheumatoid Arthritis Tagged with:Arthritis & Rheumatologybody mass index (BMI)metabolic syndromenon-TNF biologicsObesityRheumatoid Arthritis (RA)Treatmenttumor necrosis factor (TNF) inhibitors

Patients with RA in the Setting of Cardiovascular Disease

Samantha C. Shapiro, MD  |  December 3, 2024

How can we best care for our patients from a joint & cardiovascular perspective? That’s the question Christina Charles-Schoeman, MD, MS, professor of medicine and chief, Division of Rheumatology, University of California Los Angeles Medical Center, Santa Monica, Calif., addressed in a session at ACR Convergence 2024.

Filed under:ACR ConvergenceConditionsGuidanceMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2024ACR Convergence 2024 RA

Where Are We with RA? Prevention, Treatment & Management Challenges

Samantha C. Shapiro, MD  |  December 3, 2024

In this Review Course at ACR Convergence 2024, Iain McInnes, PhD, FRCP, discussed some of the challenges of RA: Remission is drug maintained, multimorbidity abounds, treatment strategies can be complex, & prevention is not yet possible.

Filed under:ACR ConvergenceConditionsRheumatoid Arthritis Tagged with:ACR Convergence 2024ACR Convergence 2024 RA

Top Research in Gout from ACR Convergence 2024 at a Glance

Lisa Stamp, MBChB, PhD  |  November 23, 2024

Dr. Lisa Stamp helps filter the noise to get to the key insights from the research abstracts on gout presented at ACR Convergence 2024.

Filed under:ACR ConvergenceConditionsGout and Crystalline ArthritisMeeting Reports Tagged with:ACR Convergence 2024ACR Convergence 2024 goutappsColchicineDECTdual-energy computed tomography (DECT)flareGoutGout Resource Centerhip replacementimagingknee replacementMicroscopyUltrasound

Fun in the Sun: The Benefits of Vitamin D

Samantha C. Shapiro, MD  |  November 23, 2024

Vitamin D has gotten a lot of press over the years. But is it actually worth the hype, especially when it comes to autoimmunity? Does it prevent the onset of autoimmune disease? Does it have a role in treatment? Experts in this ACR Convergence 2024 session helped decipher the role of vitamin D in bone health, immune regulation and infection reduction.

Filed under:ACR ConvergenceConditionsOther Rheumatic ConditionsRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:ACR Convergence 2024

Diagnosing Skin Disease in Patients with Dark Skin

Thomas R. Collins  |  November 23, 2024

Many rheumatologists may not be trained to properly identify the signs of skin disease in patients with dark skin, but in this ACR Convergence session, experts provide practical guidance for diagnosis.

Filed under:ACR ConvergenceConditionsMeeting ReportsPsoriatic ArthritisSystemic Sclerosis Tagged with:ACR Convergence 2024

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 55
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences